FibroGen Files 8-K: Bylaws Amended, Financials Filed
Ticker: KYNB · Form: 8-K · Filed: Apr 4, 2025 · CIK: 921299
| Field | Detail |
|---|---|
| Company | Fibrogen Inc (KYNB) |
| Form Type | 8-K |
| Filed Date | Apr 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, filing-update
Related Tickers: FGEN
TL;DR
FibroGen filed an 8-K on 4/4/25 for bylaw changes and financial statements.
AI Summary
FibroGen, Inc. filed an 8-K on April 4, 2025, reporting an amendment to its Articles of Incorporation or Bylaws and the filing of financial statements and exhibits. The filing date for the report is April 2, 2025. The company is incorporated in Delaware and its principal executive offices are located in San Francisco, California.
Why It Matters
This filing indicates administrative and financial updates for FibroGen, Inc., providing transparency to investors regarding corporate governance and financial reporting.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no immediate financial or operational impact disclosed.
Key Numbers
- 001-36740 — SEC File Number (Identifies the company's filing with the SEC.)
- 77-0357827 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- FibroGen, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- San Francisco, California (location) — Principal Executive Offices
- April 02, 2025 (date) — Date of earliest event reported
- April 4, 2025 (date) — Filing Date
FAQ
What specific amendments were made to FibroGen's Articles of Incorporation or Bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary text.
What financial statements were filed as part of this 8-K?
The filing states that financial statements were filed, but the specific statements (e.g., quarterly, annual) are not detailed in the provided text.
What is the significance of the 'Date as of Change' being April 4, 2025?
This date likely refers to the effective date of the reported changes or the date the information became official for reporting purposes.
What is the SIC code for FibroGen, Inc. and what does it represent?
The SIC code is 2834, which corresponds to 'Pharmaceutical Preparations'.
Where are FibroGen, Inc.'s principal executive offices located?
The principal executive offices are located at 350 Bay Street, Suite 100 #6009, San Francisco, California, 94133.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 4, 2025 regarding FIBROGEN INC (KYNB).